NCT07111000 Testing the Epley Maneuver for Treating Dizziness in the Emergency Department
| NCT ID | NCT07111000 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American University of Beirut Medical Center |
| Condition | Benign Paroxysmal Positional Vertigo (BPPV) |
| Study Type | INTERVENTIONAL |
| Enrollment | 118 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2026-07-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 118 participants in total. It began in 2024-08-01 with a primary completion date of 2026-07-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized controlled trial is to evaluate the efficacy of the Epley maneuver versus a sham maneuver in treating patients presenting to the emergency department (ED) with BPPV. The main questions that the study aims to answer are: * What is the mean difference in Dizziness Handicap Inventory (DHI) scores between patients receiving the Epley maneuver and those receiving the sham maneuver 3 days after enrollment? * What is the immediate response (using a 0-10-point Likert scale) of patients in each arm of the study? * What is the proportion of patients who, despite agreeing to participate, were unable to complete the full Epley maneuver due to symptom severity? Researchers will compare the Epley maneuver arm to the sham maneuver arm to see if the Epley maneuver is more effective in reducing BPPV symptoms. Participants will: * Undergo either the Epley maneuver or a sham maneuver. * Complete the Dizziness Handicap Inventory (DHI) questionnaire at baseline and 3 days post-discharge. * Patients with insufficient improvement in the sham maneuver group will receive a rescue Epley maneuver. * Have their vertigo severity assessed using a 0-10 point Likert scale at baseline, immediately and post-maneuver.
Eligibility Criteria
Inclusion Criteria * Age: above 18 years old * Patients presenting to the ED with symptoms of BPPV (single or recurrent episodes of vertigo lasting up to 2 minutes) and a positive DHT (episode of vertigo associated with torsional upbeating nystagmus) indicating a posterior semicircular canal BPPV. * Patients who are able to understand and provide a signed informed consent to participate in the study Exclusion Criteria * Severe cervical diseases (e.g., soft tissue disorders, cervical spondylosis, prolapsed intervertebral disks and severe rheumatoid arthritis with cervical instability …) * Unstable cardiovascular diseases (e.g., hemodynamically unstable, decompensated heart failure, acute myocardial infarction, decompensated valvular diseases, severe arrhythmias …) * Suspected vertebrobasilar diseases (e.g., cerebellar signs, vision changes, numbness or tingling in the extremities, slurred speech, changes in mental status, confusion …) * History of high-grade carotid stenosis * Recent (\<24 hours) intake of aminoglycosides, chemotherapeutic agents, cyclophosphamide, loop diuretics, or quinines * Patients with peripheral causes of vertigo other than BPPV (such as Meniere's disease or vestibular neuritis) * Patients with central causes of vertigo (vestibular migraine, Arnold Chiari malformation, history of CNS tumor(s), multiple sclerosis) * Patients with focal deficits on neurological exam * Patients with an episode of vertigo lasting more than 2 minutes * Patients with a negative DHT * Patients with pure horizontal or vertical nystagmus * Patients with lateral and anterior semicircular canals BPPV * Participants refusing to undergo Epley maneuver * Pregnancy beyond the 24th week of gestation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07111000 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Benign Paroxysmal Positional Vertigo (BPPV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07111000 currently recruiting?
Yes, NCT07111000 is actively recruiting participants. Contact the research team at eh16@aub.edu.lb for enrollment information.
Where is the NCT07111000 trial being conducted?
This trial is being conducted at Beirut, Lebanon.
Who is sponsoring the NCT07111000 clinical trial?
NCT07111000 is sponsored by American University of Beirut Medical Center. The trial plans to enroll 118 participants.